Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue Forecast
Question
Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue Forecast
Direct answer
Sustained medical device procedure volume and diagnostics demand drive 13.52% revenue expansion, expanding ABT operating margins. — bullish pressure on ABT via medtech revenue growth supporting forward operating margin expansion.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-13
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue Forecast”, revision 1, evidence through 2026-10-13. https://marketontology.com/catalysts/2026-10-13/abbott-sets-q3-2026-earnings-release-for-october-21-with-12-91b-revenue-forecast-3ca7f3
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABT | ▲Bull | 1–4 weeks | medtech revenue growth supporting forward operating margin expansion | 69 |
Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue Forecast
Sustained medical device procedure volume and diagnostics demand drive 13.52% revenue expansion, expanding ABT operating margins. — bullish pressure on ABT via medtech revenue growth supporting forward operating margin expansion.
Q3 earnings expected Oct 21 with consensus EPS $1.42 (+9.23% YoY) and revenue $12.91B (+13.52% YoY).
- SourceQ3 earnings expected Oct 21 with consensus EPS $1.42 (+9.23% YoY) and revenue $12.91B (+13.52% YoY).
- TransmissionSustained medical device procedure volume and diagnostics demand drive 13.52% revenue expansion, expanding ABT operating margins.
- SummaryAbbott is scheduled to publish third-quarter earnings on October 21, 2026. Consensus expectations project EPS of $1.42, representing 9.23% year-over-year expansion. Quarterly revenue is anticipated at $12.91 billion, up 13.52% YoY.
- ABTDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- ABT closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABT price vs. pre-event level
- ABT volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Abbott (ABT) Gains As Market Dips: What You Should Know · zacks_research · 2026-10-12
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-13Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecastABT
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.